Last 12 months
Inside the activity.
5 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 5 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 03, 2022 Filed Oct 5, 2022 21:39 UTC |
Mehta KishanDirector
|
Exercise / conversionCommon Shares | 10,000 | $1.86 | $18,600.00 |
DisclosureSEC source: 0001562180-22-007081 · primarydocument.xml · nonDerivative · entry 6 Mehta Kishan · CIK 0001850520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,378 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:39 UTC |
Mehta KishanDirector
|
Exercise / conversionCommon Shares | 7,500 | $2.58 | $19,350.00 |
DisclosureSEC source: 0001562180-22-007081 · primarydocument.xml · nonDerivative · entry 5 Mehta Kishan · CIK 0001850520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,378 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:39 UTC |
Mehta KishanDirector
|
Exercise / conversionCommon Shares | 6,502 | $4.61 | $29,974.22 |
DisclosureSEC source: 0001562180-22-007081 · primarydocument.xml · nonDerivative · entry 4 Mehta Kishan · CIK 0001850520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,878 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:39 UTC |
Mehta KishanDirector
|
Exercise / conversionCommon Shares | 4,119 | $4.84 | $19,935.96 |
DisclosureSEC source: 0001562180-22-007081 · primarydocument.xml · nonDerivative · entry 3 Mehta Kishan · CIK 0001850520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,376 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:39 UTC |
Mehta KishanDirector
|
OtherCommon Shares | 937 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-007081 · primarydocument.xml · nonDerivative · entry 2 Mehta Kishan · CIK 0001850520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,257 F2 · shares: Effective as of the Distribution, each outstanding restricted share unit of RemainCo was adjusted so that such restricted share unit became a restricted share unit in respect of Common Shares (each, an "Issuer RSU") and a restricted share unit in respect of RemainCo common shares. At the effective time of the merger of a wholly owned subsidiary of Pfizer ("Merger Sub") with and into RemainCo pursuant to the Agreement and Plan of Merger, dated as of May 9, 2022, by and among RemainCo, Pfizer and Merger Sub, the Issuer RSUs accelerated and vested in full and were subsequently settled in Common Shares. As a result, the Reporting Person acquired restricted share units in respect of Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:39 UTC |
Mehta KishanDirector
|
OtherCommon Shares | 5,320 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-007081 · primarydocument.xml · nonDerivative · entry 1 Mehta Kishan · CIK 0001850520 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,320 F1 · shares: Represents common shares of the Issuer ("Common Shares") acquired by the Reporting Person in a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"). Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:39 UTC |
GREGORY JULIA PDirector
|
GrantStock Options (Right to buy) · Derivative | 125,000 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0001562180-22-007079 · primarydocument.xml · derivative · entry 14 GREGORY JULIA P · CIK 0001226675 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Shares · 125,000 shares Expires 2032-10-04 F3 · derivative.exercise_date: The shares underlying this option vest in four equal installments on October 3, 2022, 2023, 2024, and 2025, subject to the Reporting Person's continuous service with the Issuer at each vesting date. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:39 UTC |
GREGORY JULIA PDirector
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $3.06 | $0.00 |
DisclosureSEC source: 0001562180-22-007079 · primarydocument.xml · derivative · entry 13 GREGORY JULIA P · CIK 0001226675 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 9,000 shares Expires 2029-05-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Effective as of a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"), each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire common shares of the Issuer ("Common Shares") and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement F2 · derivative.expiration_date: Effective as of a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"), each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire common shares of the Issuer ("Common Shares") and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:39 UTC |
GREGORY JULIA PDirector
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $2.33 | $0.00 |
DisclosureSEC source: 0001562180-22-007079 · primarydocument.xml · derivative · entry 12 GREGORY JULIA P · CIK 0001226675 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 9,000 shares Expires 2030-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Effective as of a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"), each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire common shares of the Issuer ("Common Shares") and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement F2 · derivative.expiration_date: Effective as of a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"), each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire common shares of the Issuer ("Common Shares") and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:39 UTC |
GREGORY JULIA PDirector
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 5,998 | $0.00 Strike: $3.56 | $0.00 |
DisclosureSEC source: 0001562180-22-007079 · primarydocument.xml · derivative · entry 11 GREGORY JULIA P · CIK 0001226675 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 5,998 shares Expires 2031-05-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Effective as of a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"), each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire common shares of the Issuer ("Common Shares") and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement F2 · derivative.expiration_date: Effective as of a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"), each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire common shares of the Issuer ("Common Shares") and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:39 UTC |
GREGORY JULIA PDirector
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 4,119 | $0.00 Strike: $4.84 | $0.00 |
DisclosureSEC source: 0001562180-22-007079 · primarydocument.xml · derivative · entry 10 GREGORY JULIA P · CIK 0001226675 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 4,119 shares Expires 2032-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Effective as of a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"), each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire common shares of the Issuer ("Common Shares") and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement F2 · derivative.expiration_date: Effective as of a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"), each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire common shares of the Issuer ("Common Shares") and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:39 UTC |
GREGORY JULIA PDirector
|
OtherStock Options (Right to Buy) · Derivative | 9,000 | Not disclosed Strike: $3.06 | Not disclosed |
DisclosureSEC source: 0001562180-22-007079 · primarydocument.xml · derivative · entry 9 GREGORY JULIA P · CIK 0001226675 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Shares · 9,000 shares Expires 2029-05-20 F2 · derivative.exercise_price: Effective as of a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"), each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire common shares of the Issuer ("Common Shares") and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement F2 · shares: Effective as of a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"), each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire common shares of the Issuer ("Common Shares") and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement F2 · price: Effective as of a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"), each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire common shares of the Issuer ("Common Shares") and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement F2 · derivative.exercise_date: Effective as of a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"), each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire common shares of the Issuer ("Common Shares") and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement F2 · derivative.expiration_date: Effective as of a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"), each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire common shares of the Issuer ("Common Shares") and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:39 UTC |
GREGORY JULIA PDirector
|
OtherStock Options (Right to Buy) · Derivative | 9,000 | Not disclosed Strike: $2.33 | Not disclosed |
DisclosureSEC source: 0001562180-22-007079 · primarydocument.xml · derivative · entry 8 GREGORY JULIA P · CIK 0001226675 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Shares · 9,000 shares Expires 2030-04-29 F2 · derivative.exercise_price: Effective as of a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"), each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire common shares of the Issuer ("Common Shares") and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement F2 · shares: Effective as of a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"), each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire common shares of the Issuer ("Common Shares") and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement F2 · price: Effective as of a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"), each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire common shares of the Issuer ("Common Shares") and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement F2 · derivative.exercise_date: Effective as of a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"), each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire common shares of the Issuer ("Common Shares") and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement F2 · derivative.expiration_date: Effective as of a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"), each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire common shares of the Issuer ("Common Shares") and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:39 UTC |
GREGORY JULIA PDirector
|
OtherStock Options (Right to Buy) · Derivative | 5,998 | Not disclosed Strike: $3.56 | Not disclosed |
DisclosureSEC source: 0001562180-22-007079 · primarydocument.xml · derivative · entry 7 GREGORY JULIA P · CIK 0001226675 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,998 Underlying: Common Shares · 5,998 shares Expires 2031-05-05 F2 · derivative.exercise_price: Effective as of a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"), each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire common shares of the Issuer ("Common Shares") and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement F2 · shares: Effective as of a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"), each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire common shares of the Issuer ("Common Shares") and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement F2 · price: Effective as of a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"), each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire common shares of the Issuer ("Common Shares") and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement F2 · derivative.exercise_date: Effective as of a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"), each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire common shares of the Issuer ("Common Shares") and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement F2 · derivative.expiration_date: Effective as of a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"), each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire common shares of the Issuer ("Common Shares") and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:39 UTC |
GREGORY JULIA PDirector
|
OtherStock Options (Right to Buy) · Derivative | 4,119 | Not disclosed Strike: $4.84 | Not disclosed |
DisclosureSEC source: 0001562180-22-007079 · primarydocument.xml · derivative · entry 6 GREGORY JULIA P · CIK 0001226675 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,119 Underlying: Common Shares · 4,119 shares Expires 2032-04-28 F2 · derivative.exercise_price: Effective as of a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"), each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire common shares of the Issuer ("Common Shares") and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement F2 · shares: Effective as of a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"), each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire common shares of the Issuer ("Common Shares") and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement F2 · price: Effective as of a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"), each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire common shares of the Issuer ("Common Shares") and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement F2 · derivative.exercise_date: Effective as of a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"), each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire common shares of the Issuer ("Common Shares") and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement F2 · derivative.expiration_date: Effective as of a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"), each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire common shares of the Issuer ("Common Shares") and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:39 UTC |
GREGORY JULIA PDirector
|
Tax withholdingCommon Shares | 11,975 | $7.50 | $89,812.50 |
DisclosureSEC source: 0001562180-22-007079 · primarydocument.xml · nonDerivative · entry 5 GREGORY JULIA P · CIK 0001226675 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,142 F1 · shares: These shares were withheld by the Issuer in connection with share settlement to cover the cost of the stock options. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:39 UTC |
GREGORY JULIA PDirector
|
Exercise / conversionCommon Shares | 9,000 | $3.06 | $27,540.00 |
DisclosureSEC source: 0001562180-22-007079 · primarydocument.xml · nonDerivative · entry 4 GREGORY JULIA P · CIK 0001226675 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,117 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:39 UTC |
GREGORY JULIA PDirector
|
Exercise / conversionCommon Shares | 9,000 | $2.33 | $20,970.00 |
DisclosureSEC source: 0001562180-22-007079 · primarydocument.xml · nonDerivative · entry 3 GREGORY JULIA P · CIK 0001226675 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,117 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:39 UTC |
GREGORY JULIA PDirector
|
Exercise / conversionCommon Shares | 5,998 | $3.56 | $21,352.88 |
DisclosureSEC source: 0001562180-22-007079 · primarydocument.xml · nonDerivative · entry 2 GREGORY JULIA P · CIK 0001226675 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,117 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:39 UTC |
GREGORY JULIA PDirector
|
Exercise / conversionCommon Shares | 4,119 | $4.84 | $19,935.96 |
DisclosureSEC source: 0001562180-22-007079 · primarydocument.xml · nonDerivative · entry 1 GREGORY JULIA P · CIK 0001226675 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,119 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:37 UTC |
HUGIN ROBERT JDirector
|
GrantStock Options (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0001562180-22-007077 · primarydocument.xml · derivative · entry 13 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Shares · 125,000 shares Expires 2032-10-04 F5 · derivative.exercise_date: The shares underlying this option vest in four equal installments on October 3, 2022, 2023, 2024, and 2025, subject to the Reporting Person's continuous service with the Issuer at each vesting date. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:37 UTC |
HUGIN ROBERT JDirector
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 9,474 | $0.00 Strike: $3.39 | $0.00 |
DisclosureSEC source: 0001562180-22-007077 · primarydocument.xml · derivative · entry 12 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 9,474 shares Expires 2030-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:37 UTC |
HUGIN ROBERT JDirector
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 5,998 | $0.00 Strike: $3.56 | $0.00 |
DisclosureSEC source: 0001562180-22-007077 · primarydocument.xml · derivative · entry 11 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 5,998 shares Expires 2031-05-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:37 UTC |
HUGIN ROBERT JDirector
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 4,119 | $0.00 Strike: $4.84 | $0.00 |
DisclosureSEC source: 0001562180-22-007077 · primarydocument.xml · derivative · entry 10 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 4,119 shares Expires 2032-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:37 UTC |
HUGIN ROBERT JDirector
|
OtherStock Options (Right to Buy) · Derivative | 9,474 | Not disclosed Strike: $3.39 | Not disclosed |
DisclosureSEC source: 0001562180-22-007077 · primarydocument.xml · derivative · entry 9 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,474 Underlying: Common Shares · 9,474 shares Expires 2030-06-09 F4 · derivative.exercise_price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · shares: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:37 UTC |
HUGIN ROBERT JDirector
|
OtherStock Options (Right to Buy) · Derivative | 5,998 | Not disclosed Strike: $3.56 | Not disclosed |
DisclosureSEC source: 0001562180-22-007077 · primarydocument.xml · derivative · entry 8 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,998 Underlying: Common Shares · 5,998 shares Expires 2031-05-05 F4 · derivative.exercise_price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · shares: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:37 UTC |
HUGIN ROBERT JDirector
|
OtherStock Options (Right to Buy) · Derivative | 4,119 | Not disclosed Strike: $4.84 | Not disclosed |
DisclosureSEC source: 0001562180-22-007077 · primarydocument.xml · derivative · entry 7 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,119 Underlying: Common Shares · 4,119 shares Expires 2032-04-28 F4 · derivative.exercise_price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · shares: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:37 UTC |
HUGIN ROBERT JDirector
|
Tax withholdingCommon Shares | 3,263 | $7.50 | $24,472.50 |
DisclosureSEC source: 0001562180-22-007077 · primarydocument.xml · nonDerivative · entry 6 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,486 F3 · shares: These shares were withheld by the Issuer in connection with share settlement to cover the cost of the stock options. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:37 UTC |
HUGIN ROBERT JDirector
|
Exercise / conversionCommon Shares | 9,474 | $3.39 | $32,116.86 |
DisclosureSEC source: 0001562180-22-007077 · primarydocument.xml · nonDerivative · entry 5 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,749 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:37 UTC |
HUGIN ROBERT JDirector
|
Exercise / conversionCommon Shares | 5,998 | $3.56 | $21,352.88 |
DisclosureSEC source: 0001562180-22-007077 · primarydocument.xml · nonDerivative · entry 4 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,275 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:37 UTC |
HUGIN ROBERT JDirector
|
Exercise / conversionCommon Shares | 4,119 | $4.84 | $19,935.96 |
DisclosureSEC source: 0001562180-22-007077 · primarydocument.xml · nonDerivative · entry 3 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,277 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:37 UTC |
HUGIN ROBERT JDirector
|
OtherCommon Shares | 1,708 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-007077 · primarydocument.xml · nonDerivative · entry 2 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,158 F2 · shares: Effective as of the Distribution, each outstanding restricted share unit of RemainCo was adjusted so that such restricted share unit became a restricted share unit in respect of Common Shares (each, an "Issuer RSU") and a restricted share unit in respect of RemainCo common shares. At the effective time of the merger of a wholly owned subsidiary of Pfizer ("Merger Sub") with and into RemainCo pursuant to the Agreement and Plan of Merger, dated as of May 9, 2022, by and among RemainCo, Pfizer and Merger Sub, the Issuer RSUs accelerated and vested in full and were subsequently settled in Common Shares. As a result, the Reporting Person acquired restricted share units in respect of Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:37 UTC |
HUGIN ROBERT JDirector
|
OtherCommon Shares | 1,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-007077 · primarydocument.xml · nonDerivative · entry 1 HUGIN ROBERT J · CIK 0001232505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,450 F1 · shares: Represents common shares of the Issuer ("Common Shares") acquired by the Reporting Person in a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"). Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:35 UTC |
Bailey GregoryDirector
|
GrantStock Options (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0001562180-22-007075 · primarydocument.xml · derivative · entry 15 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Shares · 125,000 shares Expires 2032-10-04 F4 · derivative.exercise_date: The shares underlying this option vest in four equal installments on October 3, 2022, 2023, 2024, and 2025, subject to the Reporting Person's continuous service with the Issuer at each vesting date Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:35 UTC |
Bailey GregoryDirector
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $3.06 | $0.00 |
DisclosureSEC source: 0001562180-22-007075 · primarydocument.xml · derivative · entry 14 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 9,000 shares Expires 2029-05-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:35 UTC |
Bailey GregoryDirector
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $2.33 | $0.00 |
DisclosureSEC source: 0001562180-22-007075 · primarydocument.xml · derivative · entry 13 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 9,000 shares Expires 2030-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:35 UTC |
Bailey GregoryDirector
|
Exercise / conversionStock Options (Right to buy) · Derivative | 5,998 | $0.00 Strike: $3.56 | $0.00 |
DisclosureSEC source: 0001562180-22-007075 · primarydocument.xml · derivative · entry 12 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 5,998 shares Expires 2031-05-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:35 UTC |
Bailey GregoryDirector
|
Exercise / conversionStock Options (Right to buy) · Derivative | 4,119 | $0.00 Strike: $4.84 | $0.00 |
DisclosureSEC source: 0001562180-22-007075 · primarydocument.xml · derivative · entry 11 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 4,119 shares Expires 2032-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:35 UTC |
Bailey GregoryDirector
|
OtherStock Options (Right to Buy) · Derivative | 9,000 | Not disclosed Strike: $3.06 | Not disclosed |
DisclosureSEC source: 0001562180-22-007075 · primarydocument.xml · derivative · entry 10 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Shares · 9,000 shares Expires 2029-05-20 F3 · derivative.exercise_price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · shares: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:35 UTC |
Bailey GregoryDirector
|
OtherStock Options (Right to Buy) · Derivative | 9,000 | Not disclosed Strike: $2.33 | Not disclosed |
DisclosureSEC source: 0001562180-22-007075 · primarydocument.xml · derivative · entry 9 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Shares · 9,000 shares Expires 2030-04-29 F3 · derivative.exercise_price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · shares: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:35 UTC |
Bailey GregoryDirector
|
OtherStock Options (Right to Buy) · Derivative | 5,998 | Not disclosed Strike: $3.56 | Not disclosed |
DisclosureSEC source: 0001562180-22-007075 · primarydocument.xml · derivative · entry 8 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,998 Underlying: Common Shares · 5,998 shares Expires 2031-05-05 F3 · derivative.exercise_price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · shares: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:35 UTC |
Bailey GregoryDirector
|
OtherStock Options (Right to Buy) · Derivative | 4,119 | Not disclosed Strike: $4.84 | Not disclosed |
DisclosureSEC source: 0001562180-22-007075 · primarydocument.xml · derivative · entry 7 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,119 Underlying: Common Shares · 4,119 shares Expires 2032-04-28 F3 · derivative.exercise_price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · shares: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · price: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F3 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:35 UTC |
Bailey GregoryDirector
|
Tax withholdingCommon Shares | 11,975 | $7.50 | $89,812.50 |
DisclosureSEC source: 0001562180-22-007075 · primarydocument.xml · nonDerivative · entry 6 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,307,971 F2 · shares: These shares were withheld by the Issuer in connection with share settlement to cover the cost of the stock options. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:35 UTC |
Bailey GregoryDirector
|
Exercise / conversionCommon Shares | 9,000 | $3.06 | $27,540.00 |
DisclosureSEC source: 0001562180-22-007075 · primarydocument.xml · nonDerivative · entry 5 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,319,946 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:35 UTC |
Bailey GregoryDirector
|
Exercise / conversionCommon Shares | 9,000 | $2.33 | $20,970.00 |
DisclosureSEC source: 0001562180-22-007075 · primarydocument.xml · nonDerivative · entry 4 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,310,946 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:35 UTC |
Bailey GregoryDirector
|
Exercise / conversionCommon Shares | 5,998 | $3.56 | $21,352.88 |
DisclosureSEC source: 0001562180-22-007075 · primarydocument.xml · nonDerivative · entry 3 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,301,946 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:35 UTC |
Bailey GregoryDirector
|
Exercise / conversionCommon Shares | 4,119 | $4.84 | $19,935.96 |
DisclosureSEC source: 0001562180-22-007075 · primarydocument.xml · nonDerivative · entry 2 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,295,948 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:35 UTC |
Bailey GregoryDirector
|
OtherCommon Shares | 1,291,829 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-007075 · primarydocument.xml · nonDerivative · entry 1 Bailey Gregory · CIK 0001329505 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,291,829 F1 · shares: Represents common shares of the Issuer ("Common Shares") acquired by the Reporting Person in a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer"). Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:33 UTC |
Coric VladDirector · Chief Executive Officer
|
GrantStock Option (Right to Buy) · Derivative | 950,000 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0001562180-22-007074 · primarydocument.xml · derivative · entry 54 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 950,000 Underlying: Common Shares · 950,000 shares Expires 2032-10-04 F5 · derivative.exercise_date: The shares underlying this option vest in four equal installments on October 3, 2022, 2023, 2024, and 2025, subject to the Reporting Person's continuous service with the Issuer at each vesting date. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:33 UTC |
Coric VladDirector · Chief Executive Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001562180-22-007074 · primarydocument.xml · derivative · entry 53 Coric Vlad · CIK 0001704317 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 125,000 shares Expires 2024-11-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. F4 · derivative.expiration_date: Effective as of the Distribution, each outstanding option to purchase common shares of RemainCo was adjusted so that such option became an option to acquire Common Shares and an option to acquire RemainCo common shares. As a result, the Reporting Person acquired options to acquire the Issuer's Common Shares in an amount determined in accordance with the Separation Agreement. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.